AIM To study the pharmacokinetics and relative bioavailability of Wuling capsule. METHODS schisandrin B concentrations in plasma were determined by HPLC method following a single oral dose of Wuling capsule and Wuling...AIM To study the pharmacokinetics and relative bioavailability of Wuling capsule. METHODS schisandrin B concentrations in plasma were determined by HPLC method following a single oral dose of Wuling capsule and Wuling pill respectively given to 8 rabbits. The parameters of pharmacokinetics were calculated with 3P87 pharmacokinetics program. RESULTS Concentration time curves of Wuling capsule and Wuling pill conformed to an one compartment open model. The t 1/2ka , t 1/2ke , t peak and AUC of Wuling capsule were 1.23 h, 4.80 h, 3.08 h and 28.14 mg·h -1 ·L -1 , respectively. There was no significant difference between the pharmacokinetic parameters of Wuling capsule and Wuling pill. The relative bioavailability of Wuling capsule was 97.55%. CONCLUSION Two formulations are bioequivalent.展开更多
文摘AIM To study the pharmacokinetics and relative bioavailability of Wuling capsule. METHODS schisandrin B concentrations in plasma were determined by HPLC method following a single oral dose of Wuling capsule and Wuling pill respectively given to 8 rabbits. The parameters of pharmacokinetics were calculated with 3P87 pharmacokinetics program. RESULTS Concentration time curves of Wuling capsule and Wuling pill conformed to an one compartment open model. The t 1/2ka , t 1/2ke , t peak and AUC of Wuling capsule were 1.23 h, 4.80 h, 3.08 h and 28.14 mg·h -1 ·L -1 , respectively. There was no significant difference between the pharmacokinetic parameters of Wuling capsule and Wuling pill. The relative bioavailability of Wuling capsule was 97.55%. CONCLUSION Two formulations are bioequivalent.
